SANJAY MATHEW to Double-Blind Method
This is a "connection" page, showing publications SANJAY MATHEW has written about Double-Blind Method.
Connection Strength
1.503
-
Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. Neuropsychopharmacology. 2022 04; 47(5):1088-1095.
Score: 0.144
-
Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Depress Anxiety. 2021 11; 38(11):1108-1119.
Score: 0.140
-
Is Testosterone an Effective Hormonal Therapy for Women With Antidepressant-Resistant Major Depression? Am J Psychiatry. 2020 10 01; 177(10):891-894.
Score: 0.133
-
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder. Neuropsychopharmacology. 2017 Dec; 42(13):2567-2574.
Score: 0.105
-
Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety. 2014 Apr; 31(4):335-43.
Score: 0.085
-
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013 Oct; 170(10):1134-42.
Score: 0.082
-
A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol. 2011 Mar; 21(3):221-9.
Score: 0.068
-
Glutamate and anxiety disorders. Curr Psychiatry Rep. 2007 Aug; 9(4):278-83.
Score: 0.053
-
Azetukalner, a Novel KV7 Potassium Channel Opener, in Adults With Major Depressive Disorder: A Randomized Clinical Trial. JAMA Netw Open. 2025 May 01; 8(5):e2514278.
Score: 0.046
-
Improved implicit self-esteem is associated with extended antidepressant effects following a novel synergistic intervention. Mol Psychiatry. 2024 Nov; 29(11):3431-3439.
Score: 0.043
-
Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study. Neuropsychopharmacology. 2024 Jan; 49(2):467-475.
Score: 0.041
-
Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis. J Clin Psychiatry. 2022 12 12; 84(1).
Score: 0.039
-
Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. J Clin Psychiatry. 2022 11 14; 84(1).
Score: 0.039
-
A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. Am J Psychiatry. 2022 12 01; 179(12):959-968.
Score: 0.038
-
Deep Brain Stimulation for Depression Informed by Intracranial Recordings. Biol Psychiatry. 2022 08 01; 92(3):246-251.
Score: 0.036
-
The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. Eur Neuropsychopharmacol. 2021 08; 49:122-132.
Score: 0.035
-
Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. Am J Psychiatry. 2021 05 01; 178(5):437-446.
Score: 0.034
-
Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. J Clin Psychopharmacol. 2020 May/Jun; 40(3):287-292.
Score: 0.032
-
A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating ?-opioid antagonism as a treatment for anhedonia. Nat Med. 2020 05; 26(5):760-768.
Score: 0.032
-
Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients. Psychophysiology. 2020 01; 57(1):e13356.
Score: 0.030
-
Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. Depress Anxiety. 2019 03; 36(3):235-243.
Score: 0.029
-
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Mol Psychiatry. 2020 07; 25(7):1592-1603.
Score: 0.029
-
Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. Biol Psychiatry. 2017 Dec 15; 82(12):866-874.
Score: 0.027
-
Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. Neuropsychopharmacology. 2017 Mar; 42(4):844-853.
Score: 0.025
-
Assessment of the Efficacy and Safety of BMS-820836 in Patients With Treatment-Resistant Major Depression: Results From 2 Randomized, Double-Blind Studies. J Clin Psychopharmacol. 2015 Aug; 35(4):454-9.
Score: 0.023
-
Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuropsychopharmacology. 2015 Mar 13; 40(5):1084-90.
Score: 0.023
-
Hippocampal volume and the rapid antidepressant effect of ketamine. J Psychopharmacol. 2015 May; 29(5):591-5.
Score: 0.022
-
Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial. Trials. 2014 Jun 21; 15:240.
Score: 0.022
-
Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2012 Feb; 14(1):64-70.
Score: 0.018
-
Tryptophan depletion and emotional processing in healthy volunteers at high risk for depression. Biol Psychiatry. 2011 Apr 15; 69(8):804-7.
Score: 0.017
-
Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2008 Apr; 28(2):235-9.
Score: 0.014